IOs and Biomarker Assessment in Community Based Practice

Ross 1: I just wanted to go through a few general clinical issues, questions that come up all the time when I talk to general medical oncologists in community based practice. The first is where we are today in terms of biomarker assessment, particularly as it relates to IOs. What do you consider the optimal workup for patient presenting with metastatic disease? Is the workup different for a nonsmoker or a smoker? Do you see gaps between what people do in practice and what investigators are doing?